我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
26
4 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1982
进行中（未招募）
3
11.5%
已完成
9
34.6%
尚未招募
1
3.9%
招募中
终止
Unknown
撤回
2
7.7%
暂无批准数据
- A research team at Myongji Hospital has developed the Ovarian Cancer Assay, a diagnostic tool to predict chemotherapy resistance in ovarian cancer patients. - The tool uses deep neural network models and gene data analysis to predict resistance to platinum-based chemotherapy with 85% accuracy. - Clinical trials are set to begin, supported by precision medicine companies, to validate the tool's effectiveness in personalizing ovarian cancer treatment. - Key genes and pathways, including TP53, E2F1, and MYC1, were identified as important factors in understanding chemotherapy resistance mechanisms.
